Spots Global Cancer Trial Database for A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
Official Title: A Phase 2 Basket Study of Disitamab Vedotin in Adult Subjects With Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors That Express HER2
Study ID: NCT06003231
Interventions
Study Description
Brief Summary: This clinical trial is studying advanced or metastatic solid tumors. Once a solid tumor has grown very large in one spot or has spread to other places in the body, it is called advanced or metastatic cancer. Participants in this study must have head and neck squamous cell cancer, non-small cell lung cancer, endometrial cancer, or ovarian cancer. Participants must have tumors that have a marker called HER2. This clinical trial uses an experimental drug called disitamab vedotin (DV). DV is a type of antibody-drug conjugate or ADC. ADCs are designed to stick to cancer cells and kill them. In this study, all participants will get DV once every 2 weeks. This study is being done to see if DV works to treat different types of solid tumors that express HER2. It will also test how safe the drug is for participants. This trial will also study what side effects happen when participants get the drug. A side effect is anything a drug does to your body besides treating the disease.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Ironwood Cancer & Research Centers - Chandler, Chandler, Arizona, United States
Valkyrie Clinical Trials, Los Angeles, California, United States
University of California Davis, Sacramento, California, United States
Providence Medical Foundation, Santa Rosa, California, United States
Colorado West Healthcare, dba Grand Valley Oncology, Grand Junction, Colorado, United States
Yale Cancer Center, New Haven, Connecticut, United States
Eastern CT Hematology and Oncology Associates, Norwich, Connecticut, United States
University of Miami, Miami, Florida, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Karmanos Cancer Institute / Wayne State University, Detroit, Michigan, United States
HealthPartners Institute, Saint Louis Park, Minnesota, United States
St. Vincent Frontier Cancer Center, Billings, Montana, United States
Optimum Clinical Research Group, LLC (Southwest Women's Oncology), Albuquerque, New Mexico, United States
NYU Langone Hospital, Mineola, New York, United States
NYU Langone Hospital, New York, New York, United States
Duke University Medical Center, Durham, North Carolina, United States
Gabrail Cancer Center Research, LLC, Canton, Ohio, United States
Providence Portland Medical Center, Portland, Oregon, United States
Providence Portland Medical Center, Portland, Oregon, United States
Renovatio Clinical, El Paso, Texas, United States
MD Anderson Cancer Center / University of Texas, Houston, Texas, United States
Renovatio Clinical, The Woodlands, Texas, United States
Fred Hutchinson Cancer Research Center | Seattle, WA, Seattle, Washington, United States
Blacktown Hospital, Blacktown NSW, Other, Australia
Peninsula and South East Oncology, Frankston, Other, Australia
University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada
McGill University Department of Oncology / McGill University Health Centre, Montreal, Quebec, Canada
CHU de Quebec-Universite Laval, Quebec, , Canada
Contact Details
Name: Medical Monitor
Affiliation: Seagen Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
